Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

S. Marréaud · SciRah

Researcher profile · Semantic Scholar

S. Marréaud

Share profile

S. Marréaud — researcher profile on SciRah

h-index: 54
Works: 195
Citations: 17K

Most-cited papers

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
A. Eggermont, C. Blank, M. Mandalà, G. Long +25 more
2018New England Journal of Medicine1,601 citations Open access
Semantic Scholar
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial.
M. O'Brien, L. Paz-Ares, S. Marréaud, U. Dafni +17 more
2022The Lancet Oncology583 citations
Semantic Scholar
Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial
A. Bex, P. Mulders, M. Jewett, J. Wagstaff +16 more
2019JAMA Oncology482 citations Open access
Semantic Scholar
Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial.
S. Bonvalot, A. Gronchi, C. Le Péchoux, C. Swallow +23 more
2020The Lancet Oncology389 citations Open access
Semantic Scholar
Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo
A. Eggermont, M. Kicinski, C. Blank, M. Mandalà +26 more
2020JAMA Oncology376 citations Open access
Semantic Scholar
Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial.
C. Sternberg, I. Skoneczna, J. Kerst, P. Albers +25 more
2015The Lancet Oncology370 citations
Semantic Scholar
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.
A. Eggermont, C. Blank, M. Mandalà, G. Long +27 more
2021The Lancet Oncology327 citations Open access
Semantic Scholar
Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial
A. Eggermont, C. Blank, M. Mandalà, G. Long +27 more
2020Journal of Clinical Oncology234 citations Open access
Semantic Scholar
The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial.
S. Pasquali, S. Pizzamiglio, Nathan Touati, S. Litière +10 more
2019European Journal of Cancer189 citations Open access
Semantic Scholar
Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis
A. Kollár, Robin L. Jones, S. Stacchiotti, H. Gelderblom +13 more
2017Acta oncologica168 citations Open access
Semantic Scholar
Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Tr
P. Casali, J. Zalcberg, A. Le Cesne, P. Reichardt +19 more
2017Journal of Clinical Oncology163 citations Open access
Semantic Scholar
Outcome of chemotherapy in advanced synovial sarcoma patients: Review of 15 clinical trials from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group; setting a new landmark for studies in this entity.
M. Vlenterie, S. Litière, E. Rizzo, S. Marréaud +7 more
2016European Journal of Cancer151 citations
Semantic Scholar
Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial.
P. Schöffski, J. Šufliarský, H. Gelderblom, J. Blay +14 more
2018The Lancet Respiratory Medicine144 citations Open access
Semantic Scholar
High-Dose Chemotherapy and Blood Autologous Stem-Cell Rescue Compared With Standard Chemotherapy in Localized High-Risk Ewing Sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-2008.
J. Whelan, M. le Deley, U. Dirksen, G. Le Teuff +37 more
2018Journal of Clinical Oncology139 citations Open access
Semantic Scholar
Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative
P. Aftimos, M. Oliveira, A. Irrthum, D. Fumagalli +51 more
2021Cancer Discovery137 citations Open access
Semantic Scholar
Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma.
A. Eggermont, M. Kicinski, C. Blank, M. Mandalà +26 more
2022NEJM Evidence134 citations
Semantic Scholar
Preoperative Radiotherapy in Patients With Primary Retroperitoneal Sarcoma
D. Callegaro, C. Raut, T. Ajayi, D. Strauss +21 more
2022Annals of Surgery120 citations
Semantic Scholar
Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial.
P. Schöffski, A. Wozniak, B. Escudier, P. Rutkowski +14 more
2017European Journal of Cancer113 citations
Semantic Scholar
Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’
P. Schöffski, A. Wozniak, S. Stacchiotti, P. Rutkowski +19 more
2017Annals of Oncology94 citations Open access
Semantic Scholar
STRASS (EORTC 62092): A phase III randomized study of preoperative radiotherapy plus surgery versus surgery alone for patients with retroperitoneal sarcoma.
S. Bonvalot, A. Gronchi, C. Le Péchoux, C. Swallow +16 more
2019Journal of Clinical Oncology85 citations
Semantic Scholar
Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 ‘CREATE’
P. Schöffski, A. Wozniak, Bernd Kasper, S. Aamdal +22 more
2017Annals of Oncology85 citations Open access
Semantic Scholar
Pre- and Postoperative Capecitabine Without or With Oxaliplatin in Locally Advanced Rectal Cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD.
H. Schmoll, A. Stein, E. Van Cutsem, T. Price +16 more
2020Journal of Clinical Oncology80 citations Open access
Semantic Scholar
Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma.
A. Eggermont, C. Blank, M. Mandalà, G. Long +28 more
2019European Journal of Cancer75 citations
Semantic Scholar
A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: the TRUSTS trial.
B. Bui-Nguyen, J. Butrynski, N. Penel, J. Blay +8 more
2015European Journal of Cancer64 citations Open access
Semantic Scholar
Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072.
C. Benson, I. Ray-Coquard, S. Sleijfer, S. Litière +11 more
2016Gynecologic Oncology63 citations
Semantic Scholar
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.
A. Bottomley, C. Coens, J. Mierzynska, C. Blank +30 more
2021The Lancet Oncology58 citations Open access
Semantic Scholar
Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 'CaboGIST'.
P. Schöffski, O. Mir, B. Kasper, Z. Pápai +17 more
2020European Journal of Cancer58 citations
Semantic Scholar
Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant Imatinib.
A. Gronchi, S. Bonvalot, Andres Poveda Velasco, D. Kotasek +20 more
2020JAMA Surgery57 citations Open access
Semantic Scholar
Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first‐line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer‐Soft Tissue and Bone Sarcoma Group (EORTC‐STBSG)
L. Lindner, S. Litière, S. Sleijfer, C. Benson +12 more
2018International Journal of Cancer48 citations Open access
Semantic Scholar
Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials.
F. Duffaud, S. Sleijfer, S. Litière, I. Ray-Coquard +9 more
2015European Journal of Cancer45 citations
Semantic Scholar
The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 'CREATE'.
P. Schöffski, A. Wozniak, M. Leahy, S. Aamdal +11 more
2018European Journal of Cancer44 citations Open access
Semantic Scholar
Results from a Phase I Study of Lapatinib with Gemcitabine and Cisplatin in Advanced or Metastatic Bladder Cancer: EORTC Trial 30061
L. Cerbone, C. Sternberg, L. Sengeløv, Mads Agerbaek +5 more
2015Oncology40 citations
Semantic Scholar
European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Experience with Advanced/Metastatic Epithelioid Sarcoma Patients Treated in Prospective Trials: Clinical Profile and Response to Systemic Therapy.
Nathan Touati, P. Schöffski, S. Litière, I. Judson +10 more
2018Clinics in oncology38 citations Open access
Semantic Scholar
Critical impact of radiotherapy protocol compliance and quality in the treatment of retroperitoneal sarcomas: Results from the EORTC 62092‐22092 STRASS trial
R. Haas, J. Stelmes, F. Zaffaroni, N. Sauvé +17 more
2022Cancer36 citations Open access
Semantic Scholar
Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine +/- oxaliplatin in locally advanced rectal cancer: Final results of PETACC-6.
H. Schmoll, K. Haustermans, T. Price, B. Nordlinger +16 more
201835 citations
Semantic Scholar
Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME).
R. D. de Bruijn, P. Mulders, M. Jewett, J. Wagstaff +16 more
2019European Urology34 citations Open access
Semantic Scholar
Immediate versus deferred cytoreductive nephrectomy (CN) in patients with synchronous metastatic renal cell carcinoma (mRCC) receiving sunitinib (EORTC 30073 SURTIME)
A. Bex, P. Mulders, M. Jewett, J. Wagstaff +16 more
201731 citations Open access
Semantic Scholar
Outcomes of Elderly Patients with Advanced Soft Tissue Sarcoma Treated with First-Line Chemotherapy: A Pooled Analysis of 12 EORTC Soft Tissue and Bone Sarcoma Group Trials.
E. Younger, S. Litière, A. Le Cesne, O. Mir +6 more
2018The Oncologist30 citations Open access
Semantic Scholar
Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma.
A. Eggermont, A. Meshcheryakov, V. Atkinson, C. Blank +30 more
2021European Journal of Cancer27 citations Open access
Semantic Scholar
Retrospective quality control review of FDG scans in the imaging sub-study of PALETTE EORTC 62072/VEG110727: a randomized, double-blind, placebo-controlled phase III trial
Ivalina Hristova, R. Boellaard, W. Vogel, F. Mottaghy +7 more
2015European Journal of Nuclear Medicine and Molecular Imaging27 citations Open access
Semantic Scholar
Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: New recurrence-free survival results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial at three-year median follow-up.
A. Eggermont, C. Blank, M. Mandalà, G. Long +16 more
202026 citations
Semantic Scholar
A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs
M. Bagot, B. Hasan, S. Whittaker, M. Beylot-Barry +18 more
2017EJD. European journal of dermatology24 citations
Semantic Scholar
Survival of soft tissue sarcoma patients after completing six cycles of first-line anthracycline containing treatment: an EORTC-STBSG database study
A. J. Verschoor, S. Litière, S. Marréaud, I. Judson +4 more
2020Clinical Sarcoma Research23 citations Open access
Semantic Scholar
EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study of pembrolizumab versus placebo for completely resected early-stage non-small cell lung cancer (NSCLC): Outcomes in subgroups related to surgery, disease burden, and adjuvant chemotherapy use.
M. O'Brien, L. Paz-Ares, N. Jha, U. Dafni +16 more
2022Journal of Clinical Oncology20 citations
Semantic Scholar
A multinational, multi-tumour basket study in very rare cancer types: The European Organization for Research and Treatment of Cancer phase II 90101 'CREATE' trial.
J. Péron, S. Marréaud, D. Staelens, T. Raveloarivahy +6 more
2019European Journal of Cancer17 citations Open access
Semantic Scholar
Efficacy of busulfan-melphalan high dose chemotherapy consolidation (BuMel) in localized high-risk Ewing sarcoma (ES): Results of EURO-EWING 99-R2 randomized trial (EE99R2Loc).
J. Whelan, M. le Deley, U. Dirksen, I. Judson +16 more
201617 citations
Semantic Scholar
Pembrolizumab vs placebo for early-stage non‒small-cell lung cancer after resection and adjuvant therapy: Subgroup analysis of patients who received adjuvant chemotherapy in the phase 3 PEARLS/KEYNOTE-091 study.
K. Oselin, B. Shim, M. Okada, M. Bryl +16 more
2023Journal of Clinical Oncology16 citations Open access
Semantic Scholar
Long term outcome data from the EORTC 75111-10114 ETF/BCG randomized phase II study: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer, followed by T-DM1 after progression
H. Wildiers, T. Meyskens, S. Marréaud, L. dal Lago +8 more
2022Breast15 citations Open access
Semantic Scholar
Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-1506-STBSG "ANITA".
P. Schöffski, M. Toulmonde, A. Estival, G. Marquina +15 more
2021European Journal of Cancer15 citations Open access
Semantic Scholar
New benchmarks to design clinical trials with advanced or metastatic liposarcoma or synovial sarcoma patients: An EORTC - Soft Tissue and Bone Sarcoma Group (STBSG) meta-analysis based on a literature review for soft-tissue sarcomas.
G. Kantidakis, S. Litière, An Neven, M. Vinches +10 more
2022European Journal of Cancer13 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

S. Litière×19
Invite
S. Litière — researcher profile on SciRah
H. Gelderblom×16
Invite
H. Gelderblom — researcher profile on SciRah
P. Rutkowski×15
Invite
P. Rutkowski — researcher profile on SciRah
W. V. D. van der Graaf×13
Invite
W. V. D. van der Graaf — researcher profile on SciRah

×13

Invite

P. Schöffski — researcher profile on SciRah

Invite

C. Blank — researcher profile on SciRah

Invite

A. Gronchi — researcher profile on SciRah

Invite

I. Judson — researcher profile on SciRah

Invite

J. Blay — researcher profile on SciRah

Invite

M. Mandalà — researcher profile on SciRah

Invite

G. Long — researcher profile on SciRah

Invite

V. Atkinson — researcher profile on SciRah